Literature DB >> 28956216

CREB, NF-Y and MEIS1 conserved binding sites are essential to balance Myostatin promoter/enhancer activity during early myogenesis.

Carla Vermeulen Carvalho Grade1,2, Carolina Stefano Mantovani1, Marina Alves Fontoura1, Faisal Yusuf3, Beate Brand-Saberi3, Lúcia Elvira Alvares4.   

Abstract

Myostatin (MSTN) is a strong inhibitor of skeletal muscle growth in human and other vertebrates. Its transcription is controlled by a proximal promoter/enhancer (Mstn P/E) containing a TATA box besides CREB, NF-Y, MEIS1 and FXR transcription factor binding sites (TFBSs), which are conserved throughout evolution. The aim of this work was to investigate the role of these TFBSs on Mstn P/E activity and evaluate the potential of their putative ligands as Mstn trans regulators. Mstn P/E mutant constructs were used to establish the role of conserved TFBSs using dual-luciferase assays. Expression analyses were performed by RT-PCR and in situ hybridization in C2C12 myoblasts and E10.5 mouse embryos, respectively. Our results revealed that CREB, NF-Y and MEIS1 sites are required to balance Mstn P/E activity, keeping Mstn transcription within basal levels during myoblast proliferation. Furthermore, our data showed that NF-Y site is essential, although not sufficient, to mediate Mstn P/E transcriptional activity. In turn, CREB and MEIS1 binding sites seem to depend on the presence of NF-Y site to induce Mstn P/E. FXR appears not to confer any effect on Mstn P/E activity, except in the absence of all other conserved TFBS. Accordingly, expression studies pointed to CREB, NF-Y and MEIS1 but not to FXR factors as possible regulators of Mstn transcription in the myogenic context. Altogether, our findings indicated that CREB, NF-Y and MEIS1 conserved sites are essential to control basal Mstn transcription during early myogenesis, possibly by interacting with these or other related factors.

Entities:  

Keywords:  C2C12; CREB; FXR; MEIS1; Myogenesis; Myostatin; NF-Y; Promoter

Mesh:

Substances:

Year:  2017        PMID: 28956216     DOI: 10.1007/s11033-017-4126-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  59 in total

Review 1.  The CREB family of transcription activators.

Authors:  P K Brindle; M R Montminy
Journal:  Curr Opin Genet Dev       Date:  1992-04       Impact factor: 5.578

2.  Prolonged absence of myostatin reduces sarcopenia.

Authors:  Victoria Siriett; Leanne Platt; Mônica Senna Salerno; Nicholas Ling; Ravi Kambadur; Mridula Sharma
Journal:  J Cell Physiol       Date:  2006-12       Impact factor: 6.384

3.  Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle.

Authors:  R Kambadur; M Sharma; T P Smith; J J Bass
Journal:  Genome Res       Date:  1997-09       Impact factor: 9.043

4.  Determinants of myogenic specificity within MyoD are required for noncanonical E box binding.

Authors:  Analeah B Heidt; Anabel Rojas; Ian S Harris; Brian L Black
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

Review 5.  Gene regulatory networks and transcriptional mechanisms that control myogenesis.

Authors:  Margaret Buckingham; Peter W J Rigby
Journal:  Dev Cell       Date:  2014-02-10       Impact factor: 12.270

6.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues.

Authors:  Xinmin Zhang; Duncan T Odom; Seung-Hoi Koo; Michael D Conkright; Gianluca Canettieri; Jennifer Best; Huaming Chen; Richard Jenner; Elizabeth Herbolsheimer; Elizabeth Jacobsen; Shilpa Kadam; Joseph R Ecker; Beverly Emerson; John B Hogenesch; Terry Unterman; Richard A Young; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

7.  CREB represses transcription of fos promoter: role of phosphorylation.

Authors:  R Ofir; V J Dwarki; D Rashid; I M Verma
Journal:  Gene Expr       Date:  1991-04

8.  An evolutionarily conserved Myostatin proximal promoter/enhancer confers basal levels of transcription and spatial specificity in vivo.

Authors:  Carla Vermeulen Carvalho Grade; Mônica Senna Salerno; Frank R Schubert; Susanne Dietrich; Lúcia Elvira Alvares
Journal:  Dev Genes Evol       Date:  2010-01-06       Impact factor: 0.900

9.  Expression profile of myostatin mRNA during the embryonic organogenesis of domestic chicken (Gallus gallus domesticus).

Authors:  N R Sundaresan; V K Saxena; Rani Singh; Preeti Jain; K P Singh; D Anish; Nischal Singh; M Saxena; K A Ahmed
Journal:  Res Vet Sci       Date:  2007-11-26       Impact factor: 2.534

10.  FHL3 differentially regulates the expression of MyHC isoforms through interactions with MyoD and pCREB.

Authors:  Yunxia Zhang; Wentao Li; Mingfei Zhu; Yuan Li; Zaiyan Xu; Bo Zuo
Journal:  Cell Signal       Date:  2015-10-22       Impact factor: 4.315

View more
  5 in total

Review 1.  The animal nuclear factor Y: an enigmatic and important heterotrimeric transcription factor.

Authors:  Guilin Li; Hang Zhao; Lijun Wang; Ying Wang; Xingqi Guo; Baohua Xu
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

2.  Target Gene Prediction of Transcription Factor Using a New Neighborhood-regularized Tri-factorization One-class Collaborative Filtering Algorithm.

Authors:  Hansaim Lim; Lei Xie
Journal:  ACM BCB       Date:  2018 Aug-Sep

Review 3.  Homeobox gene Meis1 modulates cardiovascular regeneration.

Authors:  Swagatika Paul; Xiaonan Zhang; Jia-Qiang He
Journal:  Semin Cell Dev Biol       Date:  2019-10-14       Impact factor: 7.727

4.  Decoding the transcriptome of denervated muscle at single-nucleus resolution.

Authors:  Hongchun Lin; Xinxin Ma; Yuxiang Sun; Hui Peng; Yanlin Wang; Sandhya Sara Thomas; Zhaoyong Hu
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-06-20       Impact factor: 12.063

Review 5.  Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation.

Authors:  Sandra Pérez-Baos; Iván Prieto-Potin; Jorge A Román-Blas; Olga Sánchez-Pernaute; Raquel Largo; Gabriel Herrero-Beaumont
Journal:  Front Physiol       Date:  2018-04-24       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.